Lilly's Weekly Efsitora Alfa Insulin Achieves A1C Reduction Comparable to Daily Insulin Administration
Tuesday, 10 September 2024, 18:40
Lilly's weekly Efsitora Alfa Insulin offers a promising advancement in diabetes care, demonstrating an A1C reduction comparable to daily insulin protocols. During clinical trials, Efsitora achieved a substantial decrease of 1.34% in A1C levels, effectively matching insulin degludec which had an A1C reduction of 1.26%. Results support the potential of Efsitora to redefine treatment options for diabetic patients.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.